Skip to main content
. 2021 Jul 16;10:381. Originally published 2021 May 13. [Version 2] doi: 10.12688/f1000research.52100.2

Figure 1. palmar psoriasis before (1a) and after (1b) treatment with secukinumab over 4 months.

Figure 1.

Manifestations of HS localized in the inguinofemoral region before (1c) and after (1d) treatment. Pyoderma gangrenosum two months after adalimumab discontinuation (1e), clinical image 4 months after secukinumab treatment (1f) and post-prednisolone i.v pulse therapy (1g). Plantar pustulosis before (1h) and after secukinumab treatment (1i).